U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

You searched for: Subject "immunogenicity" Remove constraint Subject: "immunogenicity"
Start Over

Search

2,495  Search Results

« Previous | 1 - 20 of 2,495 |
Number of results to display per page

Search Results

1. Fungal sugars boost vaccine protection

Author:
Michail S. Lionakis
Source:
Cell 2022 v.185 no.4 pp. 579-581
ISSN:
0092-8674
Subject:
immunogenicity,   etc   ; fungi; glycoproteins; lymph; mannans; vaccines;     Show all 6 Subjects
Abstract:
... In this issue of Cell, Borriello et al. show that soluble fungal mannans elicit potent innate immune responses within skin-draining lymph nodes. These can be exploited for effective development of adaptive immune responses against viral glycoproteins, thus enhancing vaccine immunogenicity and protection. ...
DOI:
10.1016/j.cell.2022.01.020

2. Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?

Author:
Hazel M. Dockrell; Egle Butkeviciute
Source:
Vaccine 2022 v.40 no.11 pp. 1525-1533
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; BCG vaccine; live vaccines; tuberculosis; vaccination;     Show all 5 Subjects
Abstract:
... The BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss what has been learnt about the BCG vaccine in the last two decades, and whether this new information can be exploited to improve its efficacy, by enhancing its ability to induce either antige ...
DOI:
10.1016/j.vaccine.2021.01.068

3. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study

Author:
Timo Vesikari; Xavier Saez-Llorens; Vezna Blazevic; Pio Lopez; Eduardo Lopez; Taisei Masuda; Paul M. Mendelman; Mengya Liu; James Sherwood; Frank Baehner; Astrid Borkowski
Source:
Vaccine 2022 v.40 no.26 pp. 3588-3596
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; gastroenteritis; genotype; vaccines; Colombia; Finland; Panama;     Show all 7 Subjects
Abstract:
... Young children can suffer severe consequences of norovirus gastroenteritis. We performed a dose-finding study of a bivalent virus-like particle (VLP) vaccine candidate (TAK-214) in healthy 1–8-year-old children. In this phase 2 study two age cohorts (1–3 and 4–8 years of age inclusive, N = 120 per cohort) of children enrolled from Finland, Panama and Colombia were initially randomized 1:1:1:1 to f ...
DOI:
10.1016/j.vaccine.2022.04.089

4. Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review

Author:
Tatyana Kushner; Vivian Huang; Robert Janssen
Source:
Vaccine 2022 v.40 no.21 pp. 2899-2903
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; antibodies; congenital abnormalities; premature birth; vaccination; vaccines;     Show all 6 Subjects
Abstract:
... There are currently no published data on the use of HepB-CpG (HEPLISAV-B®) during pregnancy or in women with documented pregnancies in the post-vaccination period. We aimed to evaluate data from the clinical development program of HepB-CpG in women who became pregnant during study participation and follow up. We identified all study participants in the HepB-CpG pivotal pre-licensure clinical trial ...
DOI:
10.1016/j.vaccine.2022.04.027

5. Expression and immunogenicity analysis of the capsid proteins of porcine circovirus types 2 to 4

Author:
Weilong Ji; Xinwei Zhang; Guyu Niu; Si Chen; Xue Li; Lin Yang; Liying Zhang; Linzhu Ren
Source:
International journal of biological macromolecules 2022 v.218 pp. 828-838
ISSN:
0141-8130
Subject:
immunogenicity,   etc   ; Porcine circovirus; capsid; cross reaction; viruses;     Show all 5 Subjects
Abstract:
... Porcine circovirus (PCV) comprises four types, PCV1, PCV2, PCV3, and PCV4, which belong to the Circovirus genus of the family Circoviridae. PCV1 is nonpathogenic, whereas PCV2, PCV3, and PCV4 can infect pigs and cause disease. However, due to a lack of experimental evidence, whether vaccines based on PCV capsid (Cap) can induce cross-reactivity against PCVs remains controversial. In this study, re ...
DOI:
10.1016/j.ijbiomac.2022.07.204

6. Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials

Author:
Feng-Cai Zhu; Hao Zeng; Jing-Xin Li; Bin Wang; Fan-Yue Meng; Feng Yang; Jiang Gu; Hao-Yu Liang; Yue-Mei Hu; Pei Liu; Liu-Sheng Peng; Xiao-Kui Hu; Yuan Zhuang; Min Fan; Hai-Bo Li; Zhong-Ming Tan; Ping Luo; Peng Zhang; Kai Chu; Jin-Yong Zhang; Ming Zeng; Quan-Ming Zou
Source:
Vaccine 2022 v.40 no.23 pp. 3216-3227
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; Staphylococcus aureus; hospitals; pathogens; placebos; vaccination; vaccines;     Show all 7 Subjects
Abstract:
... Staphylococcus aureus is an important pathogen that causes hospital and community infections. To control Staphylococcus aureus infection and reduce the usage of antibiotics, we evaluated the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in healthy adults. We conducted a randomized, double-blind, placebo-controlled phase 1a study and a randomized, ope ...
DOI:
10.1016/j.vaccine.2022.04.034

7. Immunogenicity and humanization of single‐domain antibodies

Author:
Martin A. Rossotti; Kasandra Bélanger; Kevin A. Henry; Jamshid Tanha
Source:
FEBS journal 2022 v.289 no.14 pp. 4304-4327
ISSN:
1742-464X
Subject:
immunogenicity,   etc   ; Camelidae; antibodies; epitopes; genes; humans; risk; sharks;     Show all 8 Subjects
Abstract:
... Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy‐chain antibodies, have many desirable properties as components of biologic drugs. However, their sequences may increase the risk of immunogenicity and antidrug antibody (ADA) development in humans, and thus, sdAbs are routinely humanized during development. Here, we review and summarize the available evide ...
DOI:
10.1111/febs.15809

8. Immunogenicity-boosted cancer immunotherapy based on nanoscale metal-organic frameworks

Author:
Qing Li; Ying Liu; Yanru Zhang; Wei Jiang
Source:
Journal of controlled release 2022 v.347 pp. 183-198
ISSN:
0168-3659
Subject:
immunogenicity,   etc   ; adjuvants; biodegradability; cancer therapy; immunostimulants; immunosuppression; immunotherapy; neoplasms;     Show all 8 Subjects
Abstract:
... Immunotherapy, including checkpoint blockade immunotherapy (CBI), has witnessed remarkable progress in cancer therapy. Nonetheless, significant obstacles to successful immunotherapy remain. Notably, tumour non-responsiveness to immunotherapy due to immunosuppressive tumour microenvironments (TMEs). To revitalize immunosuppressive TMEs various therapeutic strategies have been reported by researcher ...
DOI:
10.1016/j.jconrel.2022.05.003

9. Supramolecular cancer photoimmunotherapy based on precise peptide self-assembly design

Author:
Yamei Liu; Lu Zhang; Rui Chang; Xuehai Yan
Source:
Chemical communications 2022 v.58 no.14 pp. 2247-2258
ISSN:
1364-548X
Subject:
immunogenicity,   etc   ; cancer vaccines; immune response; immunotherapy; metastasis; neoplasms; peptides;     Show all 7 Subjects
Abstract:
... Combinational photoimmunotherapy (PIT) is considered to be an ideal strategy for the treatment of highly recurrent and metastatic cancer, because it can ablate the primary tumor and provide in situ an autologous tumor vaccine to induce the host immune response, ultimately achieving the goal of controlling tumor growth and distal metastasis. Significant efforts have been devoted to enhancing the im ...
DOI:
10.1039/d1cc06355c

10. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults

Author:
Daniel Drazan; Hanna Czajka; Jason D. Maguire; Jean-Louis Pregaldien; Roger Maansson; Robert O'Neill; Annaliesa S Anderson; Paul Balmer; Johannes Beeslaar; John L Perez
Source:
Vaccine 2022 v.40 no.2 pp. 351-358
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; antibodies; blood serum; complement; humans; serotypes; vaccination; vaccines;     Show all 8 Subjects
Abstract:
... The MenB-FHbp vaccine is licensed to prevent meningococcal serogroup B disease on either a 2-dose (0, 6 months) or 3-dose (0, 1–2, 6 months) series. This phase 3 study further assessed the immunogenicity and safety of the 2-dose MenB-FHbp schedule.Subjects 10–25 years of age received MenB-FHbp (months 0, 6) and the quadrivalent meningococcal conjugate vaccine MenACWY-CRM (month 0). Primary immunog ...
DOI:
10.1016/j.vaccine.2021.11.053

11. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats

Author:
Yan Ma; Zhifang Ying; Jingyan Li; Qin Gu; Xiaoyu Wang; Lukui Cai; Li Shi; Mingbo Sun
Source:
Biologicals 2022 v.75 pp. 3-11
ISSN:
1045-1056
Subject:
immunogenicity,   etc   ; antibody formation; antigens; seroconversion; serotypes; vaccination; vaccines;     Show all 7 Subjects
Abstract:
... Reducing the amount of antigen is an important strategy to resolve the present shortage of IPV supply for global polio eradication. In the study, we compared the immunogenicity of adjuvanted and non-adjuvanted fractional-dose of IPV made from Sabin strains (sIPV) by intradermal (ID) administration versus the full-dose of sIPV by intramuscular (IM) administration in rats by comparing seroconversion ...
DOI:
10.1016/j.biologicals.2022.01.005

12. Polysaccharides-based nanofibrils: From tissue engineering to biosensor applications

Author:
E. Soroush; Z. Mohammadpour; M. Kharaziha; H.R. Bakhsheshi-Rad; F. Berto
Source:
Carbohydrate polymers 2022 v.291 pp. 119670
ISSN:
0144-8617
Subject:
immunogenicity,   etc   ; biocompatibility; biosensors; cellulose nanofibers; chitin; drugs; toxicity;     Show all 7 Subjects
Abstract:
... Carbohydrate-based nanofibrils, including cellulose nanofibrils (CNFs) and chitin nanofibrils (ChNFs) are highly ordered architectures which are the basis of various biological components with hierarchical features, low-cost, biocompatibility, and biofunctionality. To preserve these exceptional structural topographies and to directly use these natural nanofibrils assembly, different approaches hav ...
DOI:
10.1016/j.carbpol.2022.119670

13. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines—Correlates of Immunogenicity Parameters with Protection

Author:
Zoltan Vajo
Source:
Viruses 2022 v.14 no.2 pp. -
ISSN:
1999-4915
Subject:
immunogenicity,   etc   ; Severe acute respiratory syndrome coronavirus 2; vaccines; viruses;     Show all 4 Subjects
Abstract:
... During the assessment and licensing of novel vaccines, as well as post licensure follow up, it is critical to have reliable immunogenicity testing methods that relate well to real life protection [...] ...
DOI:
10.3390/v14020196

14. Quantification of mRNA cap-modifications by means of LC-QqQ-MS

Author:
Nils Muthmann; Petr Špaček; Dennis Reichert; Melissa van Dülmen; Andrea Rentmeister
Source:
Methods 2022 v.203 pp. 196-206
ISSN:
1046-2023
Subject:
immunogenicity,   etc   ; S-adenosylmethionine; liquid chromatography; methyltransferases; tandem mass spectrometry;     Show all 5 Subjects
Abstract:
... Enzymatic modification of the 5′-cap is a versatile approach to modulate the properties of mRNAs. Transfer of methyl groups from S-adenosyl-l-methionine (AdoMet) or functional moieties from non-natural analogs by methyltransferases (MTases) allows for site-specific modifications at the cap. These modifications have been used to tune translation or control it in a temporal manner and even influence ...
DOI:
10.1016/j.ymeth.2021.05.018

15. Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2

Author:
Anita Verma; Mahtab Moayeri; Christopher P. Mocca; Danielle O'Mard; Qian Ma; Stephen H. Leppla; Drusilla L. Burns
Source:
Vaccine 2022 v.40 no.32 pp. 4318-4321
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; anthrax; anthrax toxin; antibody formation; morphogenesis; neoplasms; vaccines;     Show all 7 Subjects
Abstract:
... Anthrax protective antigen (PA), the receptor-binding component of anthrax toxin, elicits toxin-neutralizing antibodies which provide protection against anthrax disease. PA binds to two mammalian receptors, capillary morphogenesis protein-2 (CMG2) and tumor endothelial marker-8 (TEM8). We previously observed that binding of PA to its receptors plays a role in eliciting a strong toxin-neutralizing ...
DOI:
10.1016/j.vaccine.2022.06.023

16. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology

Author:
Suvi Heinimäki; Vili Lampinen; Kirsi Tamminen; Minna M. Hankaniemi; Maria Malm; Vesa P. Hytönen; Vesna Blazevic
Source:
Virology 2022 v.566 pp. 89-97
ISSN:
0042-6822
Subject:
immunogenicity,   etc   ; Orthomyxoviridae; antibody formation; glycoproteins; hemagglutinins; influenza; peptides; vaccines; virology;     Show all 9 Subjects
Abstract:
... Virus-like particles (VLPs) modified through different molecular technologies are employed as delivery vehicles or platforms for heterologous antigen display. We have recently created a norovirus (NoV) VLP platform, where two influenza antigens, the extracellular domain of matrix protein M2 (M2e) or the stem domain of the major envelope glycoprotein hemagglutinin (HA2) are displayed on the surface ...
DOI:
10.1016/j.virol.2021.12.001

17. Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy

Author:
Wenbo Han; Xiaopin Duan; Kaiyuan Ni; Youyou Li; Christina Chan; Wenbin Lin
Source:
Biomaterials 2022 v.280 pp. 121315
ISSN:
0142-9612
Subject:
immunogenicity,   etc   ; biocompatible materials; blood circulation; cholesterol; cytotoxicity; ferroptosis; hydrolysis; immunotherapy;     Show all 8 Subjects
Abstract:
... Dihydroartemisinin (DHA) has shown cytotoxicity against various tumor cells in vitro in an iron-dependent manner, but its in vivo antitumor efficacy is compromised by its rapid degradation and clearance. Here we show the induction of ferroptosis by DHA in an immunogenic fashion and the maximization of in vivo antitumor efficacy of DHA by co-delivering a cholesterol derivative of DHA (Chol-DHA) and ...
DOI:
10.1016/j.biomaterials.2021.121315

18. Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine in Older Adults in Taiwan: A Phase III, Randomized, Multi-center Study

Author:
Jau-Yuan Chen; Szu-Min Hsieh; Shinn-Jang Hwang; Chiu-Shong Liu; Xiaoling Li; Marion Fournier; Ting-Yu Yeh; J. Kevin Yin; Sandrine I. Samson
Source:
Vaccine 2022 pp. -
ISSN:
0264-410X
Subject:
immunogenicity,   etc   ; descriptive studies; geometry; hemagglutination; influenza; influenza vaccines; seroconversion; Taiwan;     Show all 8 Subjects
Abstract:
... High-dose influenza vaccine offers better protection against influenza/associated complications compared with standard-dose formulation. We evaluated immunogenicity and safety of high-dose influenza vaccine (QIV-HD) and standard-dose (QIV-SD) in older adults (≥65 years) in Taiwan. This was a phase III, randomized, modified double-blind, active-controlled, multi-center, descriptive study in older a ...
DOI:
10.1016/j.vaccine.2022.09.078

19. Recent advances in biomaterial-assisted cell therapy

Author:
Yu Chen; Samira Pal; Quanyin Hu
Source:
Journal of materials chemistry B 2022 v.10 no.37 pp. 7222-7238
ISSN:
2050-7518
Subject:
immunogenicity,   etc   ; affordability; antigens; biocompatible materials; biopharmaceuticals; biotechnology; chemistry; therapeutics; toxicity;     Show all 9 Subjects
Abstract:
... With the outstanding achievement of chimeric antigen receptor (CAR)-T cell therapy in the clinic, cell-based medicines have attracted considerable attention for biomedical applications and thus generated encouraging progress. As the basic construction unit of organisms, cells harbor low immunogenicity, desirable compatibility, and a strong capability of crossing various biological barriers. Howeve ...
DOI:
10.1039/d2tb00583b

20. Designing antibodies as therapeutics

Author:
Paul J. Carter; Arvind Rajpal
Source:
Cell 2022 v.185 no.15 pp. 2789-2805
ISSN:
0092-8674
Subject:
immunogenicity,   etc   ; antibodies; brain; digestive tract; drugs; risk assessment; therapeutics;     Show all 7 Subjects
Abstract:
... Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit. These topics include enhancing antibodies for c ...
DOI:
10.1016/j.cell.2022.05.029